Supernus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Revises Earnings Guidance for the Full Year of 2018; Provides Tax Rate Guidance for the Fourth Quarter of 2018
November 06, 2018 at 04:15 pm EST
Share
Supernus Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported total revenue of $102,996,000 compared to $80,398,000 a year ago. Operating earnings was $37,475,000 compared to $22,342,000 a year ago. Earnings before income taxes were $36,371,000 compared to $22,910,000 a year ago. Net earnings was $28,011,000 or $0.52 per diluted share compared to $15,961,000 or $0.29 per diluted share a year ago.
For the nine months, the company reported total revenue of $292,963,000 compared to $213,803,000 a year ago. Operating earnings was $104,589,000 compared to $65,197,000 a year ago. Earnings before income taxes were $101,409,000 compared to $65,558,000 a year ago. Net earnings was $85,100,000 or $1.57 per diluted share compared to $43,626,000 or $0.82 per diluted share a year ago.
For the year 2018, the company is updating its prior guidance. Net product sales in the range of $388 million to $395 million compared to the previously expected range of $385 million to $400 million. Operating earnings in the range of $120 million to $125 million, compared to the previously expected range of $115 million to $125 million.
For the fourth quarter of 2018, the company expects an effective tax rate of approximately 23% to 25%.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Supernus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Revises Earnings Guidance for the Full Year of 2018; Provides Tax Rate Guidance for the Fourth Quarter of 2018